AR090291A1 - Compuestos basados en la imidazo[1,2-b]piridazina, composiciones que la comprenden y metodos que los utilizan - Google Patents
Compuestos basados en la imidazo[1,2-b]piridazina, composiciones que la comprenden y metodos que los utilizanInfo
- Publication number
- AR090291A1 AR090291A1 ARP130100764A ARP130100764A AR090291A1 AR 090291 A1 AR090291 A1 AR 090291A1 AR P130100764 A ARP130100764 A AR P130100764A AR P130100764 A ARP130100764 A AR P130100764A AR 090291 A1 AR090291 A1 AR 090291A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- halo
- cyano
- or1c
- hydrocarbyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
También se revelan composiciones que comprenden a dichos compuestos reivindicados. Trastornos del SNC (Alzheimer, Parkinson). Reivindicación 1: Un método para inhibir la actividad de una quinasa asociada a adaptador 1 (AAK1), que comprende poner en contacto la AAK1 con un compuesto de la fórmula (1) o con una sal farmacéuticamente aceptable del mismo, en donde: R¹ es R¹A o hidrocarbilo C₁₋₁₂ o heterocarbilo de 2 - 12 miembros, opcionalmente sustituidos, en donde la sustitución opcional es con uno o más R¹A; cada R¹A es, de manera independiente, -OR¹C, -N(R¹C)₂, -C(O)R¹C, -C(O)OR¹C, -C(O)N(R¹C)₂, -N(R¹C)C(O)OR¹C, ciano, halo, hidrocarbilo C₁₋₁₂ o heterocarbilo de 2 - 12 miembros, opcionalmente sustituidos, en donde la sustitución opcional es con uno o más R¹B; cada R¹B es, de manera independiente, -OR¹C, -N(R¹C)₂, -C(O)R¹C, -C(O)OR¹C, C(O)N(R¹C)₂, -N(R¹C)C(O)OR¹C, ciano o halo; cada R¹C es, de manera independiente, hidrógeno o hidrocarbilo C₁₋₁₂ o heterocarbilo de 2 - 12 miembros, opcionalmente sustituidos, en donde la sustitución opcional es con uno o más de ciano, halo o hidroxilo; R² es -NR²AR²B, en donde R²A es hidrógeno y R²B es hidrocarbilo C₁₋₁₂ o heterocarbilo de 2 - 12 miembros, opcionalmente sustituidos, en donde la sustitución opcional es con uno o más R²C; o R²A y R²B se toman juntos para formar un heterociclo de 4 - 7 miembros, opcionalmente sustituido, con uno o más R²C; cada R²C es, de manera independiente, -OR²D, -N(R²D)₂, -C(O)R²D, -C(O)OR²D, -C(O)N(R²D)₂, -N(R²D)C(O)OR²D, ciano, halo, hidrocarbilo C₁₋₁₂ o heterocarbilo de 2 - 12 miembros, opcionalmente sustituidos, en donde la sustitución opcional es con uno o más amino, ciano, halo, hidroxilo o R²D; cada R²D es, de manera independiente, hidrógeno o hidrocarbilo C₁₋₁₂ o heterocarbilo de 2 - 12 miembros, opcionalmente sustituidos, en donde la sustitución opcional es con uno o más de amino, ciano, halo o hidroxilo; y R³ es hidrógeno o alquilo C₁₋₆, opcionalmente sustituido, con uno o más de ciano, halo o hidroxilo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261608758P | 2012-03-09 | 2012-03-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR090291A1 true AR090291A1 (es) | 2014-11-05 |
Family
ID=48014284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130100764A AR090291A1 (es) | 2012-03-09 | 2013-03-11 | Compuestos basados en la imidazo[1,2-b]piridazina, composiciones que la comprenden y metodos que los utilizan |
Country Status (20)
Country | Link |
---|---|
US (3) | US8969565B2 (es) |
EP (1) | EP2822559B1 (es) |
JP (1) | JP6418949B2 (es) |
KR (1) | KR102085121B1 (es) |
CN (1) | CN104470523B (es) |
AR (1) | AR090291A1 (es) |
AU (1) | AU2013230119B2 (es) |
BR (1) | BR112014022271B1 (es) |
CA (1) | CA2866164C (es) |
ES (1) | ES2676826T3 (es) |
HK (1) | HK1203407A1 (es) |
IL (1) | IL234485A (es) |
MX (1) | MX347917B (es) |
NZ (1) | NZ630719A (es) |
RU (1) | RU2014140739A (es) |
SG (1) | SG11201405563VA (es) |
TW (1) | TW201341385A (es) |
UY (1) | UY34669A (es) |
WO (1) | WO2013134219A1 (es) |
ZA (1) | ZA201406148B (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2210891A1 (en) * | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
US9416132B2 (en) | 2011-07-21 | 2016-08-16 | Tolero Pharmaceuticals, Inc. | Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors |
EP2834243B1 (en) | 2012-03-09 | 2018-04-25 | Lexicon Pharmaceuticals, Inc. | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE |
US8901305B2 (en) | 2012-07-31 | 2014-12-02 | Bristol-Myers Squibb Company | Aryl lactam kinase inhibitors |
JP2016509066A (ja) | 2013-02-22 | 2016-03-24 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | アダプター関連キナーゼ1(aak1)の阻害剤としての5h−クロメノ[3,4−c]ピリジン |
AR097543A1 (es) * | 2013-09-06 | 2016-03-23 | Lexicon Pharmaceuticals Inc | COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO |
WO2015054358A1 (en) | 2013-10-11 | 2015-04-16 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
JP6458038B2 (ja) * | 2013-12-10 | 2019-01-23 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | IL−12、IL−23および/またはIFNα応答のモジュレーターとして有用なイミダゾピリダジン化合物 |
ES2735729T3 (es) * | 2014-01-24 | 2019-12-20 | Turning Point Therapeutics Inc | Macrociclos de diarilo como moduladores de proteínas cinasas |
CN106132951B (zh) * | 2014-01-31 | 2019-02-12 | 百时美施贵宝公司 | 基于喹啉的激酶抑制剂 |
TW201620911A (zh) * | 2014-03-17 | 2016-06-16 | 雷西肯製藥股份有限公司 | 銜接子關聯激酶1之抑制劑、包含其之組成物、及其使用方法 |
US20170239249A1 (en) * | 2014-09-30 | 2017-08-24 | Bristol-Myers Squibb Company | Quinazoline-based kinase inhibitors |
EP3215509B1 (en) | 2014-11-06 | 2020-02-26 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
JP6734860B2 (ja) | 2014-11-06 | 2020-08-05 | リソソーマル・セラピューティクス・インコーポレイテッドLysosomal Therapeutics Inc. | 置換ピラゾロ[1,5−a]ピリミジンおよび医療疾患の治療におけるその使用 |
ES2958391T3 (es) | 2014-11-06 | 2024-02-08 | Bial R&D Invest S A | Imidazo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos |
US10174044B2 (en) | 2015-04-10 | 2019-01-08 | Bristol-Myers Squibb Company | Fused pyridines as kinase inhibitors |
US10316044B2 (en) | 2015-07-02 | 2019-06-11 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
BR112018000297A2 (pt) * | 2015-07-06 | 2018-09-04 | Tp Therapeutics Inc | polimorfo de macrociclo de diarila |
BR112018001065A2 (pt) | 2015-07-21 | 2018-09-11 | Tp Therapeutics, Inc. | macrociclos diarila quirais e usos dos mesmos |
WO2017087590A1 (en) * | 2015-11-18 | 2017-05-26 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
CA3020287A1 (en) | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics Inc. | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
MX2018012208A (es) | 2016-04-06 | 2019-03-28 | Lysosomal Therapeutics Inc | Compuestos a base de imidazo [1,5-a] pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos. |
JP7034935B2 (ja) | 2016-04-06 | 2022-03-14 | リソソーマル・セラピューティクス・インコーポレイテッド | ピロロ[1,2-a]ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用 |
MX2018012664A (es) * | 2016-04-15 | 2019-03-07 | Blueprint Medicines Corp | Inhibidores de quinasa tipo receptor de activina. |
WO2017192930A1 (en) | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
WO2017192931A1 (en) | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
MX2019001125A (es) | 2016-07-28 | 2019-06-12 | Tp Therapeutics Inc | Inhibidores de cinasa macrociclica. |
GB201617758D0 (en) | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
KR20180088113A (ko) * | 2017-01-26 | 2018-08-03 | 한미약품 주식회사 | 이미다조피리다진 화합물 |
JP7082608B2 (ja) | 2017-03-14 | 2022-06-08 | 第一三共株式会社 | 3,6-ジ置換イミダゾ[1,2-b]ピリダジン誘導体の製造方法 |
CN107082828B (zh) * | 2017-05-19 | 2019-09-17 | 暨南大学 | 一种活性氧响应性高分子载体及其制备方法 |
BR112020001695A2 (pt) | 2017-07-28 | 2020-07-21 | Turning Point Therapeutics, Inc. | compostos macrocíclicos e usos dos mesmos |
US10899733B2 (en) | 2017-08-23 | 2021-01-26 | Oregon Health & Science University | Inhibitors of PARPs that catalyze mono-ADP-ribosylation |
ES2929467T3 (es) | 2017-12-19 | 2022-11-29 | Turning Point Therapeutics Inc | Compuestos macrocíclicos para tratar enfermedades |
WO2020167990A1 (en) | 2019-02-12 | 2020-08-20 | Tolero Pharmaceuticals, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
CN110684028B (zh) * | 2019-10-28 | 2021-10-26 | 上海阿拉丁生化科技股份有限公司 | 一种2,6-二氮杂双环[3,3,0]辛烷类化合物的制备方法 |
US20230159542A1 (en) * | 2020-04-21 | 2023-05-25 | The Uab Research Foundation | Rna-binding protein multimerization inhibitors and methods of use thereof |
KR102590438B1 (ko) * | 2020-10-16 | 2023-10-18 | 김홍렬 | Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 예방 또는 소독용 조성물 |
KR102590444B1 (ko) * | 2020-10-16 | 2023-10-18 | 김홍렬 | Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 치료용 조성물 |
CN117120090A (zh) * | 2021-02-12 | 2023-11-24 | 林伯士萨顿公司 | Hpk1拮抗剂和其用途 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
US7750000B2 (en) * | 2005-09-02 | 2010-07-06 | Bayer Schering Pharma Ag | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments |
US20070078136A1 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
EP2063962A2 (en) | 2006-09-07 | 2009-06-03 | Biogen Idec MA Inc. | Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder |
WO2008052734A1 (en) * | 2006-10-30 | 2008-05-08 | Novartis Ag | Heterocyclic compounds as antiinflammatory agents |
FR2934994B1 (fr) * | 2008-08-12 | 2010-09-17 | Sanofi Aventis | Derives de 2-alkyl-6cycloamino-3-(pyridin-4-yl)imidaz°1,2-b! pyridazine, leur preparation et leur application en therapeutique |
RS53350B (en) * | 2008-09-22 | 2014-10-31 | Array Biopharma, Inc. | SUBSTITUTED COMPOUNDS OF IMIDASO [1,2-B] PYRIDASINE AS INK KINASE INHIBITORS |
DK2822555T3 (en) * | 2012-03-09 | 2018-02-05 | Lexicon Pharmaceuticals Inc | Inhibition of adapter-associated kinase 1 for the treatment of pain |
EP2834243B1 (en) | 2012-03-09 | 2018-04-25 | Lexicon Pharmaceuticals, Inc. | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE |
-
2013
- 2013-03-05 MX MX2014010584A patent/MX347917B/es active IP Right Grant
- 2013-03-05 CN CN201380021272.3A patent/CN104470523B/zh active Active
- 2013-03-05 US US13/785,271 patent/US8969565B2/en active Active
- 2013-03-05 JP JP2014561020A patent/JP6418949B2/ja active Active
- 2013-03-05 WO PCT/US2013/029043 patent/WO2013134219A1/en active Application Filing
- 2013-03-05 BR BR112014022271-1A patent/BR112014022271B1/pt active IP Right Grant
- 2013-03-05 EP EP13712953.2A patent/EP2822559B1/en active Active
- 2013-03-05 NZ NZ630719A patent/NZ630719A/en unknown
- 2013-03-05 AU AU2013230119A patent/AU2013230119B2/en active Active
- 2013-03-05 CA CA2866164A patent/CA2866164C/en active Active
- 2013-03-05 KR KR1020147028073A patent/KR102085121B1/ko active IP Right Grant
- 2013-03-05 RU RU2014140739A patent/RU2014140739A/ru not_active Application Discontinuation
- 2013-03-05 ES ES13712953.2T patent/ES2676826T3/es active Active
- 2013-03-05 SG SG11201405563VA patent/SG11201405563VA/en unknown
- 2013-03-08 TW TW102108279A patent/TW201341385A/zh unknown
- 2013-03-11 AR ARP130100764A patent/AR090291A1/es unknown
- 2013-03-11 UY UY0001034669A patent/UY34669A/es not_active Application Discontinuation
-
2014
- 2014-08-21 ZA ZA2014/06148A patent/ZA201406148B/en unknown
- 2014-09-07 IL IL234485A patent/IL234485A/en active IP Right Grant
-
2015
- 2015-02-25 US US14/631,097 patent/US20160024093A1/en not_active Abandoned
- 2015-04-29 HK HK15104152.9A patent/HK1203407A1/xx unknown
-
2016
- 2016-04-26 US US15/138,460 patent/US20170057964A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MX2014010584A (es) | 2014-09-18 |
IL234485A (en) | 2017-02-28 |
US20170057964A1 (en) | 2017-03-02 |
SG11201405563VA (en) | 2014-10-30 |
AU2013230119A1 (en) | 2014-09-25 |
CA2866164C (en) | 2020-07-07 |
US20130245021A1 (en) | 2013-09-19 |
WO2013134219A1 (en) | 2013-09-12 |
US8969565B2 (en) | 2015-03-03 |
ES2676826T3 (es) | 2018-07-25 |
EP2822559B1 (en) | 2018-05-02 |
EP2822559A1 (en) | 2015-01-14 |
UY34669A (es) | 2013-10-31 |
CN104470523A (zh) | 2015-03-25 |
TW201341385A (zh) | 2013-10-16 |
KR102085121B1 (ko) | 2020-03-05 |
US20160024093A1 (en) | 2016-01-28 |
HK1203407A1 (en) | 2015-10-30 |
AU2013230119B2 (en) | 2017-02-23 |
RU2014140739A (ru) | 2016-04-27 |
CN104470523B (zh) | 2017-07-11 |
NZ630719A (en) | 2017-01-27 |
BR112014022271B1 (pt) | 2021-09-21 |
KR20140138865A (ko) | 2014-12-04 |
JP6418949B2 (ja) | 2018-11-07 |
MX347917B (es) | 2017-05-17 |
CA2866164A1 (en) | 2013-09-12 |
BR112014022271A2 (es) | 2017-06-20 |
JP2015509534A (ja) | 2015-03-30 |
ZA201406148B (en) | 2016-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR090291A1 (es) | Compuestos basados en la imidazo[1,2-b]piridazina, composiciones que la comprenden y metodos que los utilizan | |
AR090292A1 (es) | Compuestos basados en pirazolo[1,5-a]pirimidina, composiciones que los comprenden y metodos que los utilizan | |
PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
PH12019500163A1 (en) | Tetrahydro- and dihydro-isoquinoline prmt5 inhibitors and uses thereof | |
AR097543A1 (es) | COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO | |
PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
CR20160191A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
NZ730730A (en) | Novel carboxylic acid compounds useful for inhibiting microsomal prostaglandin e2 synthase-1 | |
PH12015500064A1 (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
MX2015012850A (es) | Inhibidores de la arginina metiltransferasa y usos de los mismos. | |
MY172924A (en) | Neprilysin inhibitors | |
WO2014153100A3 (en) | Arginine methyltransferase inhibitors and uses thereof | |
WO2014153235A3 (en) | Arginine methyltransferase inhibitors and uses thereof | |
TR201905814T4 (tr) | Jak inhibitörü olarak bipirazol tuzu. | |
BR112015021983A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
AR085155A1 (es) | Procesos para preparar compuestos de quinolina y composiciones farmaceuticas que contienen dichos compuestos | |
AR097545A1 (es) | COMPUESTOS A BASE DE PIRAZOLO[1,5-a]PIRIMIDINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO | |
BR112013020996A2 (pt) | derivados aminobutíricos substituídos como inibidores de neprilisina | |
EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
MX2015008993A (es) | Radiofarmaceuticos y agentes de radio-formacion de imagen a base de triazina. | |
BR112014028042A2 (pt) | inibidores de nampt | |
CO7280475A2 (es) | Derivados de azaindol que actuan como inhibidores de pi3k | |
CU24330B1 (es) | Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |